Clinical Trials Logo

Dyslipidemias clinical trials

View clinical trials related to Dyslipidemias.

Filter by:

NCT ID: NCT01216956 Completed - Insulin Sensitivity Clinical Trials

Metabolic Effects of an 8 Week Niaspan Treatment in Patients With Abdominal Obesity and Mixed Dyslipidemia

Start date: September 2006
Phase: N/A
Study type: Interventional

Nicotinic acid (Niacin) has been used for many years for the treatment of dyslipidemia. Indeed Niacin decreases triglycerides (TG) and low density lipoprotein cholesterol (LDL-c) but more importantly increases high density lipoprotein cholesterol (HDL-c). Although the drug has been used for so long, its precise mechanism of action remains elusive. The aim of this study was to characterise the metabolic changes induced by 8 week treatment with Niacin in dyslipidemic, overweight patients. The importance of the inhibition of lipolysis on the overall lipid effects of niacin will be studied. In order to get a very comprehensive view of all metabolic activities of niacin, this study will investigate the potential effects of niacin on Glucose metabolism, lipid and lipoprotein turnover, quantitative changes in lipoproteins and key enzymes involved in lipid metabolism.

NCT ID: NCT01211847 Completed - Dyslipidemia Clinical Trials

Efficacy Study of Diazoxide Choline to Treat Hypertriglyceridemia

Start date: October 2010
Phase: Phase 2
Study type: Interventional

Once a day oral administration with DCCR helps lower triglycerides

NCT ID: NCT01205750 Completed - Obesity Clinical Trials

Hepatic Insulin Sensitivity and Very Low Density Lipoprotein Triglyceride (VLDL-TG) Kinetics

Start date: March 2010
Phase: N/A
Study type: Interventional

Obesity is associated with dyslipidemia, which is a major risk factor for coronary heart disease. Triglycerides (TG) and cholesterol are transported in the system of lipoproteins, and the metabolism of these lipids in plasma is closely interrelated. Evidence suggests that increased concentration of very low-density lipoprotein triglyceride (VLDL-TG) is a central pathophysiological feature of the lipid and lipoprotein abnormalities in dyslipidemia. The primary objective of this study is to investigate VLDL-TG kinetics and hepatic insulin sensitivity in age-matched obese and lean, healthy men in the postabsorptive state and during acute hyperinsulinemia using VLDL-TG and glucose tracers.

NCT ID: NCT01165853 Completed - Metabolic Syndrome Clinical Trials

Effects of Consuming Sugar-Sweetened Beverages With Meals for 10 Weeks

IPOP
Start date: July 2005
Phase: N/A
Study type: Interventional

The purpose of this study is compare the effects of consuming glucose- and fructose-sweetened beverages on appetite, body weight, body fat, and the amount of energy the body burns as well as effects on blood pressure, hormones, blood triglycerides and cholesterol, and the body's sensitivity to the insulin.

NCT ID: NCT01164397 Completed - Dyslipidemia Clinical Trials

Efficiency of Rosuvastatin Versus the Fixed Combination of Ezetimibe/Simvastatin in Outpatients

Start date: April 2009
Phase: N/A
Study type: Observational

The aim of this study is to evaluate the effectiveness of Rosuvastatin versus Ezetimibe/Simvastatin in dyslipidemic patients treated for at least 8 weeks.

NCT ID: NCT01163851 Completed - Clinical trials for Hypercholesterolemia

Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin

Start date: July 2010
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to evaluate the pharmacokinetics and pharmacodynamics of a single dose of PF-04950615 (RN316) in volunteers on stable doses of atorvastatin. PF-04950615 (RN316) is an investigational drug that is currently being studies as a cholesterol lowering therapy.

NCT ID: NCT01122667 Completed - Dyslipidemia Clinical Trials

Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)

Start date: June 2010
Phase: Phase 1
Study type: Interventional

This study will evaluate the Area Under the Curve (AUC(0 to infinity)) of anacetrapib in subjects with impaired renal function and healthy matched control subjects.

NCT ID: NCT01114490 Completed - Dyslipidemia Clinical Trials

Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)

Start date: May 2010
Phase: Phase 1
Study type: Interventional

This study will evaluate the Area Under the Curve (AUC(0 to infinity)) of anacetrapib.

NCT ID: NCT01113099 Completed - Diabetes Clinical Trials

Improving Adherence to Prescribing Guidelines for Cholesterol Lowering in Hospitalized Diabetic Patients

Start date: June 2006
Phase: N/A
Study type: Interventional

We hypothesize that when compared to usual care a greater proportion of hospitalized diabetic patients who are candidates for cholesterol lowering will be discharged with a prescription for a statin if their physicians are contacted by a pharmacist to discuss treatment guidelines.

NCT ID: NCT01112423 Completed - Dyslipidemia Clinical Trials

Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

Start date: June 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on LDL cholesterol (LDL-C)